Cytiva is expanding its ability to support customers through a strategic collaboration that expands our lyophilization (lyo) manufacturing capabilities across the U.S. and EMEA. Collaborating with Argonaut Manufacturing Services, we are broadening our global presence to more effectively address customer needs for localized production, regulatory compliance (ISO13485 or GMP), and supply chain resilience, regardless of project size, from small to large batches.
Lyophilization (freeze-drying) plays a critical role in the stabilization of reagents and biologics, preserving their efficacy for transport and long-term storage, and eliminating the need for cold-chain shipping, which benefits the environment. Customers in diagnostics and pharmaceuticals are increasingly looking for partners offering end-to-end lyophilization process services within their region to minimize transit times, overcome customs challenges, and ensure lyophilized product stability. Through this collaboration, Cytiva is positioned to meet that demand more effectively.
Why this matters
The ability to manufacture and distribute lyophilized products closer to customers has become a key industry requirement. Recent research highlighted that many companies now prioritize local manufacturing over global supply chains when selecting a lyophilization partner. The driving factors behind this shift include:
- Regulatory and compliance considerations – For customers in diagnostics and biopharmaceuticals, adhering to global regulatory requirements is crucial.GMP-certified manufacturing (if required), provides a strategic advantage.
- Supply chain efficiency and sustainability – International shipping delays and customs clearance bottlenecks pose significant challenges when transporting reagents and buffers to manufacturing sites for lyophilization. A regional manufacturing presence reduces these risks by keeping production closer to the point of use, enhancing sustainability.
- Product integrity and stability – Reducing transit times minimizes exposure to environmental variations that can affect the quality and reliability of the reagents and buffers during lyophilization.
By addressing these challenges, we strengthen our capability to support customers throughout the lyophilization process, from development and lyophilization optimization to large-scale commercialization.
What this means for customers
With this expansion, Cytiva customers benefit from:
- Regulatory compliance – ISO13485 and GMP-certified production (if required) ensures regulatory alignment and quality assurance for sensitive applications globally.
- Reduced logistical hurdles – Shorter transit times, fewer regulatory complexities, and a more streamlined, sustainable supply chain.
- Flexible, scalable lyophilization services – Lyophilization expertise tailored to meet customer needs at various production scales, from early-stage development to full commercial manufacturing.
- Improved market responsiveness – Regional production allows customers to more rapidly adapt to market demands and supply fluctuations.
By collaborating with a specialized contract manufacturer, Cytiva extends its manufacturing flexibility while maintaining direct customer relationships and delivering the high standards of quality and service that customers expect.
Looking ahead
This strategic expansion underscores Cytiva’s commitment to advancing its global diagnostic assay development capabilities and delivering solutions that meet real-world customer needs. As we move forward, we will continue to explore ways to optimize our manufacturing footprint and ensure that our customers receive the highest level of support, regardless of where they operate.